Last updated on November 2017

Phase III Gout Study

Brief description of study

Phase III Gout Study

Detailed Study Description

This long term study evaluates the safety and efficacy of an investigational treatment compared to allopurinol in people who have both gout and cardiovascular disease. Participants will receive compensation for their time and travel; $50 for each completed office visit and $15 for each completed telephone call throughout the study. There are up to 7 scheduled visits in the first year and every 6 months thereafter. The study is expected to last approximately 5 years. Study medication, examinations and bloodwork will be provided at no cost.

Patient Inclusion Criteria:

  • History of cardiovascular disease

Patient Exclusion Criteria:

  • History of Hep B, Hep C, or HIV.

Clinical Study Identifier: TX1205

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )